Overview

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This is a single-center, Phase 1, randomized, double-blind, 6-way crossover study to determine insulin pharmacokinetics, insulin glucodynamics, safety, and tolerability of subcutaneously administered dose(s) of insulin lispro + recombinant human hyaluronidase PH20 (rHuPH20), insulin lispro alone, insulin glulisine + rHuPH20, insulin glulisine alone, insulin aspart + rHuPH20, and insulin aspart alone.

Phase:

Phase 1

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin Aspart
Insulin glulisine
Insulin Lispro
Insulin, Globin Zinc